Kymera Therapeutics 주식 (NASDAQ: KYMR)

에 대한 최신 뉴스 Kymera Therapeutics (NASDAQ:KYMR) 주식

KYMERA THERAPEUTICS INC

Kymera Therapeutics

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Stuttgart,,Germany,-,08-24-2023:,Person,Holding,Cellphone,With,Website,Of

Equities

Mid Cap

News

Movers

AIFU

APLD

BPMC

CRWV

KYMR

NVCR

RIOT

RXRX

SEZL

ZLAB

어플라이드 디지털, 라이엇 플랫폼스 등 지난주 급등한 중형주 10종목 (6월 2일~6일)

QuantumScape QS Stock

General

APGE

CRNX

JOBY

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Kymera Therapeutics Inc

Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares fell 3.66% to $402.59 Monday morning after being excluded from the latest S&amp;P 500 quarterly rebalance, disappointing investors who had anticipated its inclusion.
What To Know: This setback comes amid broader industry developments. JPMorgan analyst Cory Carpenter <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on">recently raised</a> AppLovin's price forecast from $355 to $400, citing strong first-quarter results, regulatory tailwinds from the App Store ruling and optimism around its Axon 2 ad tech.
However, Needham analyst Bernie McTernan <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655193/applovins-valuation-reflects-high-expectations-for-monetization-expansion-analyst">reiterated</a> a Hold rating, pointing to modest Axon adoption growth and rising valuation concerns. McTernan noted the tool is yet to fully launch in self-service mode despite reaching 2,000 users and landing new clients like Reebok.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45838270/robinhood-stock-is-falling-monday-whats-going-on">Robinhood Stock Is Falling Monday: What&#8217;s Going On?</a>
McTernan noted that AppLovin's valuation is now among the highest in his coverage group, driven by rising investor expectations for the company's ability to expand monetization through new advertising verticals.
AppLovin meanwhile projects second-quarter revenue of $1.21 billion and EPS of $1.86, as analysts remain divided on its valuation and growth trajectory.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45838486/apples-wwdc-2025-kicks-off-today-whats-going-on">Apple&#8217;s WWDC 2025 Kicks Off Today: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy APP Stock</h2>
By now you're likely curious about how to participate in the market for AppLovin &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, APP has a 52-week high of $525.04 and a 52-week low of $60.67.

AppLovin Stock Falls As S&P 500 Snub Dampens Sentiment

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight and lowers the price target from $71 to $53.

Price Target

Analyst Ratings

CYTK

JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $53

Redburn Atlantic analyst Charles Bendit upgrades LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) from Neutral to Buy and raises the price target from $420 to $460.

Upgrades

LPLA

Redburn Atlantic Upgrades LPL Finl Hldgs to Buy, Raises Price Target to $460

Redburn Atlantic analyst Charles Bendit upgrades Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) from Sell to Neutral and raises the price target from $65 to $82.

SCHW

Redburn Atlantic Upgrades Charles Schwab to Neutral, Raises Price Target to $82

Shares of Know Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NASDAQ">KNW</a>) surged again Monday, climbing 104.2% to $3.19 in early trading, extending Friday's rally. The momentum follows news that Goldeneye 1995 LLC, led by former Ripple Chief Risk Officer Greg Kidd, will acquire a controlling stake in Know Labs.
What To Know: On Friday, KNW soared over 200% after announcing the deal. The acquisition will be financed using 1,000 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and cash, valuing the stock at $0.335 per share. 
Despite that valuation, investor enthusiasm has pushed the stock well above that level, likely reflecting optimism over the company's new Bitcoin-focused strategy.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45838546/gamestop-gme-stock-volatile-ahead-of-earnings-boosted-by-bitcoin-bet-and-switch-2-hype">GameStop Stock Volatile Ahead Of Earnings, Boosted By Bitcoin Bet And Switch 2 Hype</a>
Kidd will become CEO and chairman under the agreement, expected to close in third-quarter 2025. The new leadership plans to hold Bitcoin as a treasury asset, with BTC anticipated to comprise 82% of the company's market cap if priced at $105,000. Kidd called the strategy a "forward-looking move to drive sustainable growth."
Founder Ron Erickson will remain with the company, leading a new division for non-invasive diagnostics and serving as vice chairman. The board unanimously approved the deal.
With Monday&#8217;s volume spiking to over 90 million shares, far above its 100-day average, the stock remains a speculative but highly active play.
<h2 class="wp-block-heading">How To Buy KNW Stock</h2>
By now you're likely curious about how to participate in the market for Know Labs &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, KNW has a 52-week high of $4.20 and a 52-week low of $0.33.
Image: Shutterstock

$BTC

Know Labs (KNW) Stock Jumps Again Monday On Bitcoin-Backed Acquisition Momentum

Stephens &amp; Co. analyst Charles Nabhan maintains NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) with a Overweight and raises the price target from $12 to $15.

Stephens & Co. Maintains Overweight on NCR Voyix, Raises Price Target to $15

Shares of electric vertical take-off and landing (eVTOL) companies Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and Joby Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) are rising Monday, extending gains from Friday following executive orders aimed at boosting electric air taxis and <a href="https://www.benzinga.com/news/politics/25/06/45826882/trump-signs-orders-to-strengthen-us-drone-defenses-and-supersonic-flight">supersonic commercial aircraft</a>.
What To Know: President Donald Trump on Friday signed multiple executive orders focused on &#8220;Unleashing American Drone Dominance.&#8221; The orders aim to strengthen U.S. defenses against drone threats and boost electric air taxi aircraft. 
&#8220;Drones are already transforming industries from logistics and infrastructure inspection to precision agriculture, emergency response, and public safety. Emerging technologies such as electric Vertical Takeoff and Landing (eVTOL) aircraft promise to modernize methods for cargo delivery, passenger transport, and other advanced air mobility capabilities,&#8221; the executive order states. 
The Trump administration will establish a federal task force focused on controlling U.S. airspace. The orders also call for the establishing of a pilot program to increase adoption of eVTOL technology. The administration said it aims to &#8220;accelerate the deployment of safe and lawful eVTOL operations&#8221; in the U.S.
Joby shares traded higher last week after the company announced an <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45748130/joby-aviation-stock-is-taking-off-tuesday-whats-behind-the-move">agreement</a> to explore distribution and service partnerships in&nbsp;Saudi Arabia with&nbsp;Abdul Latif Jameel. The collaboration is focused on enabling local air taxi services and building support infrastructure and could lead to the delivery of up to 200 aircraft and related services valued at approximately $1 billion over the coming years.
Archer shares have also seen increased attention in recent weeks after the company announced&nbsp;plans to deliver its first Midnight Edition aircraft to the UAE in the coming months. Archer said last week that it started&nbsp;the next phase of Midnight&#8217;s flight test program showcasing piloted flight.
&#8220;Midnight&#8217;s VTOL and CTOL capabilities are a strong differentiator for us as they are critical for delivering an aircraft that can integrate into a wide range of operational scenarios while also providing enhanced safety,&#8221; said Adam Goldstein, founder and CEO of Archer. 
ACHR, JOBY Price Action: Archer shares were up 9.42% at $11.16 and Joby shares were up 10.20% at $8.95 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45834705/mohamed-el-erian-warns-of-worrisome-chinese-trade-data-looming-over-us-negotiations-but-bob-elliott-sees-little-urgency-for-china-to-sign-a-disadvantageous-deal">Mohamed El Erian Warns Of &#8216;Worrisome&#8217; Chinese Trade Data Looming Over US Negotiations, But Bob Elliott Sees &#8216;Little Urgency&#8217; For China To Sign A &#8216;Disadvantageous Deal&#8217;</a></li>
</ul>
Photo: courtesy of Joby Aviation.

ACHR

Archer Aviation, Joby Shares Are Rising Monday: What's Driving The Momentum?

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $950 to $800.

REGN

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $800

Trading Ideas

NCPL

Netcapital Portfolio Company Zelgor Has Completed The Acquisition Of Mixie; Shares See Volume Pop To The Upside

HC Wainwright &amp; Co. analyst Brandon Folkes maintains PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy and raises the price target from $11 to $13.

PYPD

HC Wainwright & Co. Maintains Buy on PolyPid, Raises Price Target to $13

Jefferies analyst Brent Thill maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Buy and raises the price target from $190 to $200.

ORCL

Jefferies Maintains Buy on Oracle, Raises Price Target to $200

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.29% on an annualized basis producing an average annual return of 22.12%. Currently, Insulet has a market capitalization of $21.56 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $2,028.81 today based on a price of $306.35 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749483012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PODD

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Stephens &amp; Co. analyst Jim Salera reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Equal-Weight and maintains $49 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Chipotle Mexican Grill, Maintains $49 Price Target

<a href="https://www.thecaptainslog.io/groupon-glp-1-office-racket/" title="https://www.thecaptainslog.io/groupon-glp-1-office-racket/">https://www.thecaptainslog.io/groupon-glp-1-office-racket/</a>

Short Sellers

GRPN

Watching Groupon; Shares Move Lower, Traders Circulate Article By The Captain's Log Titled "Groupon Has Become a GLP-1 Affiliate Marketing and Bootleg Microsoft Office Racket"

Wolfe Research analyst Steve Fleishman downgrades Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Edison Intl to Peer Perform

Wolfe Research analyst Andrew Rosivach downgrades Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) from Outperform to Peer Perform.

EQIX

Wolfe Research Downgrades Equinix to Peer Perform

Events

Exclusives

MSOS

From Benzinga's Cannabis Capital Conference: C3 Industries CEO, Ankur Rugta Says It Is Very Hard To Do M&A Deals Right Now, Says Currently Institutional Equity Is Non-Existent In The Cannabis Sector

WIIM

UNFI

United Natural Foods shares are trading lower after the company reported unauthorized activity on certain IT systems.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Brandon Folkes initiated coverage on Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy rating and announced a price target of $6. Heron Therapeutics shares closed at $2.10 on Friday. <a href="https://www.benzinga.com/quote/hrtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst John Todaro initiated coverage on eToro Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) with a Buy rating and announced a price target of $80. Etoro Group shares closed at $68.70 on Friday. <a href="https://www.benzinga.com/quote/etor/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Ed Engel initiated coverage on Antalpha Platform Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTA#NASDAQ">ANTA</a>) with a Buy rating and announced a price target of $20. Antalpha Platform shares closed at $12.77 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Brandon Oglenski initiated coverage on Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) with an Overweight rating and announced a price target of $190. Ryder System shares closed at $150.60 on Friday. <a href="https://www.benzinga.com/quote/R/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Ryan Meyers initiated coverage on Sky Harbour Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) with a Buy rating and announced a price target of $14. Sky Harbour shares closed at $9.80 on Friday. <a href="https://www.benzinga.com/quote/SKYH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ryder stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/r/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-1024x597.png" alt="" class="wp-image-943397" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Initiation

Markets

ANTA

ETOR

HRTX

SKYH

This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Management

Press Releases

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Earnings

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

Health Care

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

ImmunityBio

Immunovant

Krystal Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Viking Therapeutics

B. Riley Securities

Morgan Stanley

JP Morgan

Stifel

지난주 가장 좋은 성과를 거든 중형주 10종목은 다음과 같다.
<ol class="wp-block-list">
<li>어플라이드 디지털(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) 주가는 AI 하이퍼스케일러 코어위브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>)와 장기 <a href="https://www.benzinga.com//node/45817409" target="_blank" rel="noreferrer noopener">인프라 계약</a> 발표 후 102.93% 상승했다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) 주가는 60.66% 급등했다. 회사는 KT-621의 건강한 자원자 1상 연구의 임상 결과를 공개했다. 모건스탠리와 B라일리 증권은 각각 투자의견을 비중 확대와 매수로 상향 조정했으며, <a href="https://www.benzinga.com/quote/kymr/analyst-ratings" target="_blank" rel="noreferrer noopener">여러 애널리스트들이 목표주가를 상향 조정했다.</a></li>
<li>퍼스트 마제스틱 실버(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) 주가는 지난 주 34.04% 증가했다. 목요일 은 가격이 온스당 35.60달러를 넘어섰으며 2012년 이후 처음 있는 일이다. 금 강세론자 피터 쉬프는 <a href="https://www.benzinga.com//node/45792880" target="_blank" rel="noreferrer noopener">지금이 급등의 시작이라고 말했다</a>.</li>
<li>AIFU(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) 주가는 31.78% 상승했다.</li>
<li>리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) 주가는 MIT와의 파트너십으로 <a href="https://www.benzinga.com//node/45814396" target="_blank" rel="noreferrer noopener">Boltz-2 출시 발표</a> 후 31.34% 상승했다.</li>
<li>클리블랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) 주가는 미국 대통령 도널드 트럼프가 <a href="https://www.benzinga.com//node/45724684" target="_blank" rel="noreferrer noopener">철강 관세를 두 배로 늘리겠다고 발표한 후</a> 30.36% 상승했다.</li>
<li>자이랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) 주가는 26.44% 상승했다. 회사와 노보큐어 리미티드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>)는 토요일에 췌장암에 대한 종양 치료 분야 (TTFields) 요법의 <a href="https://www.benzinga.com//node/45730717" target="_blank" rel="noreferrer noopener">3상 PANOVA-3 시험의 추가 데이터를 공개했다</a>.</li>
<li>블루프린트 메디슨스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) 주가는 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/45719179" target="_blank" rel="noreferrer noopener">블루프린트를 95억 달러에 인수할 것이라고 발표한 후</a> 26.15% 상승했다.</li>
<li>세즐(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) 주가는 지난 주 23.78% 상승했다.</li>
<li>라이엇 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) 주가는 22.06% 상승했다. 회사는 5월에 514 비트코인을 채굴했으며, 이는 전월 대비 11% 증가하고 <a href="https://www.benzinga.com//node/45752589" target="_blank" rel="noreferrer noopener">전년 대비 139% 증가한 수치다.</a></li>
</ol>
사진 출처: T. 슈나이더 via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kymera Therapeutics

뉴스

에 대한 최신 뉴스 Kymera Therapeutics (NASDAQ:KYMR) 주식

월요일, 6월 09, 2025

월요일, 7월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌